HONG KONG – China's Luye Pharma Group Ltd. acquired the rights of Astrazeneca plc's antipsychotics Seroquel (quetiapine fumarate) and Seroquel XR. The transaction, which will allow Luye to manufacture the drugs and market them in 51 countries and regions, is a win-win, helping Luye tap into the global market while Astrazeneca seeks to spin off products that are no longer part of its core business.
HONG KONG – China's Luye Pharma Group Ltd. acquired the rights of Astrazeneca plc's antipsychotics Seroquel (quetiapine fumarate) and Seroquel XR. The transaction, which will allow Luye to manufacture the drugs and market them in 51 countries and regions, is a win-win, helping Luye tap into the global market while Astrazeneca seeks to spin off products that are no longer part of its core business.
HONG KONG – While the South Korean government's pricing regime is helping to make drugs more affordable in the country, it is also slowing the value growth of the pharmaceutical market and pressuring the sales of innovative drugs.
HONG KONG – Sino-American biopharma company CBT Pharmaceuticals Inc. is set to work with South Korea's Crystalgenomics Inc. on an investigational combination therapy for solid tumors. The two agreed to co-develop and commercialize the final product worldwide.
HONG KONG – South Korea's Peptron Inc. is looking to advance the development of sustained-release (SR) drugs, tapping into a global licensing deal with the U.S. NIH and focusing on developing new treatments for neurodegenerative disorders.
HONG KONG – Sino-American biopharma company CBT Pharmaceuticals Inc. is set to work with South Korea's Crystalgenomics Inc. on an investigational combination therapy for solid tumors. The two agreed to co-develop and commercialize the final product worldwide.
HONG KONG – South Korea's Peptron Inc. is looking to advance the development of sustained-release (SR) drugs, tapping into a global licensing deal with the U.S. NIH and focusing on developing new treatments for neurodegenerative disorders.
HONG KONG – Emerging biotech companies can start submitting their formal listing applications in Hong Kong next month as the Stock Exchange of Hong Kong (HKEX) said that proposed new rules to broaden its listing regime will come into effect on April 30.
HONG KONG – China's Suzhou Alphamab Co. Ltd. has obtained the IND approval from regulators for its HER2 bispecific antibody, KN-026. The phase I trials will commence later this year.
